These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7359537)

  • 21. A ureido group containing analogue of oxytocin comprising eight amino acid residues.
    Bodanszky M; Fagan DT; Walter R; Smith CW
    J Med Chem; 1978 Mar; 21(3):306-8. PubMed ID: 628007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
    Smith CW; Ferger MF
    J Med Chem; 1976 Feb; 19(2):250-4. PubMed ID: 1249804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some biological properties of an "irreversible" antagonist of neurohypophyseal hormones, deamino-[Phe(4-BrCH2CONH)2]-oxytocin, and its isosteric analogue, deamino-[Phe(4-CH3CH2CONH)2]-oxytocin.
    Pliska V; Marbach P
    Eur J Pharmacol; 1978 Jun; 49(3):213-22. PubMed ID: 658139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity.
    Melin P; Vilhardt H; Lindeberg G; Larsson LE; Akerlund M
    J Endocrinol; 1981 Feb; 88(2):173-80. PubMed ID: 7193709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [4-(0-methyl)-L-threonine] -oxytocin. Synthesis and uterotonic activity.
    Bańkowski K
    Pol J Pharmacol Pharm; 1988; 40(3):331-5. PubMed ID: 2853867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and some pharmacological properties of 8-L-methionine-oxytocin.
    Bodanszky M; Chandramouli N; Martinez J; Walter R
    J Med Chem; 1979 Mar; 22(3):270-3. PubMed ID: 423209
    [No Abstract]   [Full Text] [Related]  

  • 27. Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
    Rosamond JD; Ferger MF
    J Med Chem; 1976 Jul; 19(7):873-6. PubMed ID: 940106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8.
    Flouret G; Chaloin O; Slaninová J
    J Pept Sci; 2003 Jun; 9(6):393-401. PubMed ID: 12846485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and pharmacological properties of [1-L-penicillamine,4-L-leucine]oxytocin.
    Ferger MF; Chan WY
    J Med Chem; 1975 Oct; 18(10):1020-2. PubMed ID: 1159679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and some pharmacological properties of [1-beta-mercapto-beta,beta-diethylpropionic acid,2-(3,5-dibromo-L-tyrosine)]oxytocin.
    Lundell EO; Smith CW; Ferger MF
    J Med Chem; 1975 Dec; 18(12):1262-4. PubMed ID: 1195281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
    Grzonka Z; Lammek B; Gazis D; Schwartz IL
    J Med Chem; 1983 Dec; 26(12):1786-7. PubMed ID: 6685771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiuretic and pressor activities of vasopressin analogs with L-alaninamide and D-alaninamide substitutions at position 9.
    Buku A; Gazis D; Schwartz IL
    Int J Pept Protein Res; 1984 May; 23(5):551-7. PubMed ID: 6547408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies.
    Melin P; Trojnar J; Carlsson AM; Bengtsson B; Akerlund M; Robinson I
    Eur J Pharmacol; 1988 Mar; 148(1):93-9. PubMed ID: 3383999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic antagonists of the myometrial response to vasopressin and oxytocin.
    Melin P; Trojnar J; Johansson B; Vilhardt H; Akerlund M
    J Endocrinol; 1986 Oct; 111(1):125-31. PubMed ID: 3783079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biofunctional evaluation of two hydrogen bonds stabilizing the beta-turn in the acyclic component of oxytocin.
    Roy U; Gazis D; Schwartz IL; Roy J
    Int J Pept Protein Res; 1983 Oct; 22(4):398-403. PubMed ID: 6654586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of high-performance liquid chromatography in the quality control of oxytocin, vasopressin and synthetic analogues.
    Maxl F; Siehr W
    J Pharm Biomed Anal; 1989; 7(2):211-6. PubMed ID: 2488622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity.
    Wittelsberger A; Patiny L; Slaninova J; Barberis C; Mutter M
    J Med Chem; 2005 Oct; 48(21):6553-62. PubMed ID: 16220972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of conditioned behavior of rats by neurohypophyseal hormones and analogues.
    Walter R; van Ree JM; de Wied D
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2493-6. PubMed ID: 276885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformation.
    Lebl M; Hill P; Kazmierski W; Kárászová L; Slaninová J; Fric I; Hruby VJ
    Int J Pept Protein Res; 1990 Oct; 36(4):321-30. PubMed ID: 2079387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response behavior on the isolated rat uterus of oxytocin analogs with modifications at binding sites.
    Smith CW; Chan S; Walter R
    J Pharmacol Exp Ther; 1977 Oct; 203(1):120-4. PubMed ID: 909047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.